AR and prostate cancer: In prostate cancer, ELK1-shRNA expression resulted in a significant decrease in the growth of androgen-sensitive/AR-positive LNCaP cells cultured with R1881, but not in that of LNCaP cultured without androgens or that of AR-negative cells [19].